- Research works
- 110 ▲ 45% vs 2013–17
- Citations
- 4.3k 39.1 per fractional work
- Top-10% rate
- 34.5% record average 16.5%
- Open access
- 82% world 28%
Not ranked overall: Novavax (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.8×. Every wedge is a field page.
- Immunology and Microbiology 9.8×
- Medicine 3.0×
- Veterinary 2.6×
- Biochemistry, Genetics and Molecular Biology 2.0×
- Mathematics 2.0×
- Chemistry 1.1×
- Agricultural and Biological Sciences 1.0×
- Social Sciences 0.7×
- Pharmacology, Toxicology and Pharmaceutics 0.3×
- Health Professions 0.3×
- Psychology 0.3×
- Decision Sciences 0.2×
- Economics, Econometrics and Finance 0.2×
- Computer Science 0.1×
- Neuroscience 0.1×
- Engineering 0.0×
Who are the top researchers at Novavax (United States)?
Ranked on the composite score, Gale Smith and Louis Fries lead among researchers whose main affiliation is Novavax (United States).
- 1 Gale Smith United States · #375,353 worldwide 150 citations · 19 works
- 2 Louis Fries United States · #590,132 worldwide 95 citations · 17 works
Which keywords describe research at Novavax (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Pandemic, SARS-CoV-2, Vaccine, ACE2 Receptor, Coronavirus, Epidemiology, Immunity and Viral Transmission.
- Pattern Recognition Receptors
- Innate Memory
- Cancer Immunotherapy
- Epigenetic Reprogramming
- Respiratory Syncytial Virus
- Human Metapneumovirus
- Vaccine Development
- Genomics
- Infectious Diseases
- COVID-19
- Clinical Characteristics
- Epitope Prediction
- Thrombosis
- Health Behavior
- Pathogenesis
- spike protein
- Viral Transmission
- Coronavirus
- ACE2 Receptor
- SARS-CoV-2
- Pandemic
- Vaccine
- Epidemiology
- Immunity
- antibody
- Immune Response
- Antigen Presentation
- COVID-19 Vaccine
- Vaccine Hesitancy
- Peptide-MHC Binding
- Cytokine Storm
- Circovirus
- Porcine Reproductive and Respiratory Syndrome Virus
- Influenza
- Virus
- Innate Immunity
- Monoclonal Antibodies
- Therapeutic Antibodies
- Dendritic Cells
- Trained Immunity
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Pandemic16▲ 32×5 topics
- SARS-CoV-215▲ 102×6 topics
- Vaccine14▲ 75×8 topics
- ACE2 Receptor14▲ 122×2 topics
- Epidemiology13▲ 7.0×20 topics
- Coronavirus13▲ 129×3 topics
- Immunity12▲ 65×3 topics
- Viral Transmission11▲ 154×2 topics
- antibody10▲ 210×1 topic
- spike protein10▲ 210×1 topic
- Immune Response7▲ 26×7 topics
- Pathogenesis6▲ 24×10 topics
- Antigen Presentation5▲ 114×2 topics
- Health Behavior4▲ 88×2 topics
- COVID-19 Vaccine4▲ 113×1 topic
- Thrombosis4▲ 29×2 topics
- Vaccine Hesitancy4▲ 123×1 topic
- Epitope Prediction4▲ 288×1 topic
- Peptide-MHC Binding4▲ 288×1 topic
- Clinical Characteristics3▲ 58×1 topic
- Cytokine Storm3▲ 68×1 topic
- COVID-193▲ 4.7×8 topics
- Circovirus2▲ 145×1 topic
- Infectious Diseases2▲ 14×2 topics
- Porcine Reproductive and Respiratory Syndrome Virus2▲ 145×1 topic
- Genomics2▲ 13×2 topics
- Influenza2▲ 89×1 topic
- Vaccine Development2▲ 14×3 topics
- Virus2▲ 39×1 topic
- Human Metapneumovirus2▲ 73×1 topic
- Innate Immunity2▲ 10×3 topics
- Respiratory Syncytial Virus2▲ 73×1 topic
- Monoclonal Antibodies1▲ 30×3 topics
- Epigenetic Reprogramming1▲ 28×2 topics
- Therapeutic Antibodies1▲ 38×2 topics
- Cancer Immunotherapy1▲ 16×1 topic
- Dendritic Cells1▲ 27×1 topic
- Innate Memory1▲ 109×1 topic
- Trained Immunity1▲ 109×1 topic
- Pattern Recognition Receptors1▲ 17×2 topics
Which research topics does Novavax (United States) publish most on?
By volume in 2022–2025: SARS-CoV-2 and COVID-19 Research, Vaccine Coverage and Hesitancy, vaccines and immunoinformatics approaches and COVID-19 Clinical Research Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 SARS-CoV-2 and COVID-19 Research Infectious Diseases 10 works
- 2 Vaccine Coverage and Hesitancy Health 4 works
- 3 vaccines and immunoinformatics approaches Molecular Biology 4 works
- 4 COVID-19 Clinical Research Studies Infectious Diseases 3 works
- 5 Animal Virus Infections Studies Animal Science and Zoology 2 works
- 6 Influenza Virus Research Studies Epidemiology 2 works
- 7 Respiratory viral infections research Epidemiology 2 works
- 8 Immunotherapy and Immune Responses Immunology 1 works
- 9 Immune responses and vaccinations Immunology 1 works
- 10 COVID-19 epidemiological studies Modeling and Simulation 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Novavax (United States)'s research output changed?
Output in 2018–2022 was 45% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Gaithersburg
- National Institute of Standards and Technology
- Molecular Oncology (United States)
- Scientific Consulting Group
- NIST Center for Neutron Research
- Material Measurement Laboratory
- Center for Nanoscale Science and Technology
- Information Technology Laboratory
- Robotic Research (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.